ABSTRACT. Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is a common autosomal recessive disorder of mitochondrial fatty acid oxidation characterized by episodes of hypoketotic hypoglycemia usually beginning in the first 2 y of life. W e previously showed, in pulse labeling experiments, that the biosynthesis and immediate posttranslational processing of MCAD are normal in fibroblasts from patients with MCAD deficiency. Most patients studied to date are homozygous for a point mutation (Agss-G) that results in the substitution of glutamate for lysine a t residue 304 of the mature MCAD subunit. W e performed immunoblot analysis of fibroblast MCAD from a total of 3 4 patients with MCAD deficiency, including 31 homozygous for the A985-G mutation, using a rabbit antirat MCAD antibody that cross-reacted specifically with human MCAD, but not with the related enzymes, shortchain and long-chain acyl-CoA dehydrogenases. All patients with the AgB5-G mutation lacked detectable MCAD. Pulse-chase labeling of MCAD-deficient fibroblasts with "S-methionine demonstrated that this variant MCAD was unstable compared to controls. Taken together, these data suggest that this mutation affects the stability of MCAD protein within the mitochondrial matrix. (Pediatr Res 31: [34][35][36][37][38]1992) Abbreviations CRM, cross-reacting material LCAD, long-chain acyl-CoA dehydrogenase MCAD, medium-chain acyl-CoA dehydrogenase pMCAD, precursor MCAD SCAD, short-chain acyl-CoA dehydrogenase MCAD deficiency is an autosomal recessive disorder of mitochondrial fatty acid oxidation associated with episodes of hypoketotic hypoglycemia, usually beginning in the first 2 y of life. Since its first description in [1982][1983] (1-3), more than 100 cases of MCAD deficiency have been reported, with a clinical phenotype that ranges from completely asymptomatic to an acute episode resulting in sudden infant death; its incidence may be as high as 1 in 10 000 births among Caucasians (4). MCAD is a homotetrameric flavoenzyme that catalyzes the first step in the mitochondrial oxidation of medium-chain fatty acyl-CoA (6-12 carbon chain length) and is encoded by a nuclear gene on the short arm of chromosome 1 (5). In both rat and human tissues, translation of pMCAD subunits occurs on cytoplasmic ribosomes, followed by mitochondrial uptake and cleavage of the N-terminal leader peptide to yield mature MCAD subunits (6, 7). After the addition of flavin adenine dinucleotide (1 equivalent per subunit), they are assembled into the enzymatically active tetramers.
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We have previously demonstrated in short-term (1 h) labeling experiments with 35S-methionine (7) that fibroblasts from 13 patients with MCAD deficiency synthesized a variant pMCAD subunit of normal size (46.5 kD) and intensity. This subunit was processed to a mature intramitochondrial subunit of normal size (43.5 kD) in amounts comparable to those seen in control fibroblasts. These data implied that variant MCAD in these fibroblasts probably contains a point mutation, but that at least the early steps in its biosynthesis and mitochondrial import proceed normally.
The coding region of human MCAD cDNA is 1263 bp in length and encodes the 421-amino acid pMCAD subunit (8). The amino terminus of the mature human MCAD subunit is currently unknown, but assuming that it is Lys-26, as in the case of rat MCAD (9), the first 25 amino acids constitute the leader peptide. Several laboratories (10-14) recently have reported in cells from numerous MCAD-deficient patients a single prevalent mutation, an A to G transition at position 985 (Agg5-G) of the coding region. This mutation results in a lysine-to-glutamate substitution at residue 329 of the precursor MCAD subunit, corresponding to residue 304 of the mature MCAD subunit. To date, this mutation has been reported to account for about 90% of MCAD-deficient alleles, indicating an unusually high prevalence of this point mutation.
To elucidate the biologic consequences of this mutation, we used immunoblot analysis and pulse-chase (metabolic) labeling of variant MCAD with "S-methionine in cultured fibroblasts from patients with MCAD deficiency, most of whom were homozygous for the prevalent mutation. For these experiments, we used rabbit antibodies raised against rat liver MCAD and SCAD, which were previously demonstrated to have high affinity and specificity for their human counterparts (1 5).
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of MCAD and SCAD from rat liver, MCAD-deficient patients. The diagnosis of MCAD deficiency was made using octanoyl-CoA in an electron transfer flavoprotein reduction assay (17). Residual MCAD activity in these cultures ranged from 0 to 13% of the mean of 120 controls. Normal cell cultures for this study (GM05565, GM05659, GM00038A) were from the Human Genetic Mutant Cell Repository (Camden, NJ). Disease control cultures included two from patients with LCAD deficiency, one from a patient with SCAD deficiency, and one from a patient with a carnitine transport defect. Skin fibroblasts were grown in Eagle's minimal essential medium supplemented with 10% FCS in a C 0 2 incubator at 37°C. Confluent monolayers in two 1 50-cm2 flasks were washed twice with PBS, pH 7.4, and harvested with a plastic scraper. The cell pellets were washed twice with PBS by centrifugation at 1500 rpm, collected in a microcentrifuge tube, and stored at -70°C. Under these conditions, immunoreactive proteins were stable for at least 6 mo, but the samples usually were used within 2 wk.
Extraction of cell protein. Cell pellets were thawed and extracted by incubating on ice for 30 min with 0.3 mL of extraction buffer containing 50 mM Tris-HC1, pH 7.4; 150 mM NaC1; 5 mM EDTA; 0.02% sodium azide; 0.5% Nonidet P-40; and 1 mM phenylmethylsulfonyl fluoride. Protein content was measured (1 8) and was adjusted to 2.0 mg/mL with extraction buffer.
SDS-PAGE and immunoblot analysis. Electrophoresis was
canied out on 10% polyacrylamide slab gels with a 5% stacking gel, using the discontinuous buffer system of Laemmli (19). One to 10 ng purified rat liver MCAD (in extraction buffer containing BSA at a concentration of 1 mg/mL to avoid the loss of antigen as a result of adsorption) was used as a standard on each gel. Fibroblast extracts were diluted 1:l with sample buffer containing: 125 mM Tris-HC1, pH 6.8; 4% SDS; 20% glycerol; 10% 2-mercaptoethanol; and 0.005% bromphenol blue. Aliquots containing 100 gg cell protein were applied to the gel in most experiments. In some experiments, protein content applied to the gel was varied from 6 to 300 pg/ 100 pL. In all cases, the final volume applied was 100 pL; extraction buffer was varied, with sample buffer volume remaining constant. After electrophoresis, gels were electroblotted (Transblot SD Apparatus; Bio-Rad Laboratories, Richmond, CA) to Immobilon-P membranes (Millipore, Bedford, MA). Membranes were treated as previously described (20), except that incubation with rabbit anti-rat liver MCAD or anti-rat liver SCAD antibody was for 1 h. The antigenlantibody complex was detected using the alkaline phosphatase-conjugated anti-rabbit IgG system (BioRad Laboratories).
Metabolic labeling with 35S-i?zethionine. This was performed exactly as described by Naito et al. (2 1) for the labeling of mutant SCAD-deficient fibroblasts. Briefly, cells were exposed to medium containing 100 & 35S-methionine for 1 h, followed by incubation with Eagle's minimal essential medium containing 15 mg/L unlabeled methionine for periods up to 24 h. MCAD was precipitated with anti-rat liver MCAD antibody, washed 10 times, and then electrophoresed using the Laemmli buffer system (19). 35S-labeled proteins were detected by fluorography.
Molecular analysis of MCAD mutations. This was performed as previously described (10). Fibroblasts from all 34 patients were analyzed. They included 3 1 in whom the Ag85-G transition was the only mutation identified (10; Yokota I, Coates PM, Hale DE, Tanaka K, unpublished observations); one who was heterozygous for A985-G and a rare second mutation causing a 13-bp tandem repeat insertion from position 999 in the MCAD cDNA sequence, which leads to a premature chain-terminating codon at the 5'-end of the second repeat (10, 22); and two previously unpublished, unrelated patients heterozygous for A9g5-G and an as-yet-unidentified second mutation (Yokota I, Coates PM, Hale DE, Tanaka K, unpublished observations).
Immunoblot analysis of MCAD in fibroblasts j b m controls and from patients with MCAD deficiency. Among seven controls
(three normal, two LCAD-deficient, one SCAD-deficient, and one with a carnitine transport defect), the MCAD band detected by immunoblot analysis was of predicted size (estimated as 45 kD by SDS-PAGE) and of comparable intensity. Among patients with MCAD deficiency due to the AgR5-G defect, there was either no MCAD band or a barely detectable band in the region corresponding to MCAD. Typical results are shown in Figure 1 . There are other bands with lower or higher apparent molecular weight than MCAD that can be seen in these gels. These bands are of variable intensity and can be seen in all cells, regardless of whether MCAD is present or not. Particularly, there are a few nonspecific bands in the vicinity of the MCAD band, making the results appear somewhat ambiguous. However, these nonspecific bands are much less intense than the MCAD band in controls, and their exact location differs from that of the MCAD band. Therefore, it is possible to judge whether the MCAD band is absent or a faint one is present in the MCAD-deficient cells. When membranes were incubated with rabbit preimmune serum (instead of anti-MCAD antiserum), no bands were observed.
A total of 34 patients with MCAD deficiency have now been studied, all of whom correspond to this pattern, namely no CRM, or at most a very faint band, detectable by immunoblot analysis. Cells from heterozygous parents of these patients demonstrate a prominent band of MCAD protein that is indistinguishable from controls (data not shown).
An experiment was performed to determine the detectable range of MCAD protein in control fibroblasts (Fig. 2) . Although gels generally were run with 100 pg of cell protein, the anti-MCAD antibody could detect MCAD in control cells when as little as 12.5 ~g of cell protein were applied to the gel. By contrast, there was no increase in detectable MCAD in MCAD-deficient cells, even when as much as 300 pg of cell protein were applied to the gel.
Metabolic labeling of i K A D with 35S-met/zionine. Cells from
a control and from patient no. 574 with MCAD deficiency, homozygous for Ass5-G and lacking a detectable band of MCAD protein by immunoblot analysis, were labeled with 35S-methionine for 1 h and then exposed to unlabeled methionine for 24 h. Control cells had a single immunoprecipitable band that was stable for 24 h. By contrast, cells from the patient had a very prominent MCAD band after I h of pulse, but the MCAD band had diminished in intensity after 6 h and had virtually disappeared after 24 h of exposure to unlabeled methionine (Fig. 3) .
Immunoblot analysis of SCAD in fibroblasts from controls and from patients with MCAD dejciency. All patients with MCAD deficiency, as well as all controls, had a readily detectable SCAD band when immunoblot analysis was done using anti-SCAD antibody (Fig. 4) .
DISCUSSION
The results presented here demonstrate a remarkable feature of variant MCAD in the inherited disorder MCAD deficiency. Despite normal translation and immediate posttranslational processing of MCAD in MCAD-deficient fibroblasts (7), virtually no variant MCAD protein is detectable in the steady state, suggesting that the variant MCAD protein within mitochondria in these cells is highly unstable. Thirty-one of the fibroblast cultures were from MCAD-deficient patients homozygous for a single, identical point mutation, Aqg5'G (10; Yokota I, Indo Y, Coates PM, and Tanaka K, unpublished observations). The present data suggest that this mutation affects the stability of MCAD protein within the mitochondria1 matrix. The data suggesting that variant MCAD is unstable are supported by the metabolic labeling experiments using 35S-methionine in Figure  3 , which show that variant MCAD protein disappears almost completely after 24 h of incubation with unlabeled methionine. Fig. 1 . Immunoblot analysis of MCAD in skin fibroblasts from patients with MCAD deficiency. Lane I: molecular weight markers (in kD). Lane 8: 10 ng purified rat liver MCAD. Lanes 2, 3, and 12: fibroblasts from a control subject, a patient with LCAD deficiency (LCAD), and a patient with carnitine transport defect (CTD), respectively. Lanes 4-7, 9-11, 13, and 14: fibroblasts from patients with MCAD deficiency. One hundred pg of cell protein were applied to each lane. . lmmunoblot analysis of SCAD in skin fibroblasts from patients with MCAD deficiency. Lanes I and 3-10: fibroblasts from patients with MCAD deficiency. Lunes 2 and 12: fibroblasts from control and carnitine transport defect (CTD) patients, respectively. One hundred pg of cell protein were applied to each lane. band of MCAD protein by immunoblot analysis. This patient is the same one as our patient no. 363 ( Fig. 1) with confirmed MCAD deficiency (24), and who is homozygous for the APa5-G mutation (Yokota I, Coates PM, Hale DE, Tanaka K, unpublished observations). Our data confirm the findings of Inagaki et al. in this patient. Their other patient, AH, had a detectable MCAD protein band by immunoblot analysis; it seems likely that this patient has another mutation that does not affect MCAD stability.
Several mechanisms to explain the instability of the variant MCAD product of the AgE5-G mutant allele are possible. These include inherent instability of the variant subunit and inhibition of intramitochondrial processing that occurs after cleavage of the leader peptide; the latter could be inhibition at the level of conformational changes via the action of chaperone proteins (25) or inhibition of tetramer formation. We previously noted that computer analysis predicted that the Lys-304 to Glu substitution would not cause drastic changes in the secondary structure of MCAD (10). Residue 304 is located in a domain that is not thought to be involved in flavin adenine dinucleotide binding or in substrate binding (26) , but instead may form the interface in the tetramer structure. It is an attractive hypothesis that substitution of a basic residue in this region with a n acidic one may hinder tetramer formation or disrupt normal tetramer structure (10, 12, 13).
